China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND) filing for its freeze-dried respiratory syncytial virus (RSV) mRNA vaccine has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
RSV and Vaccine Technology
RSV is a common viral pathogen causing acute lower respiratory tract infections, particularly in susceptible populations such as the elderly and infants. Abogen’s vaccine utilizes proprietary base modification technology and a nanoliposome delivery system (LNP), which is patented in China, the US, Australia, and Europe.
Storage Stability
The mature freeze-drying process allows the vaccine to be stored stably for more than 2 years under mild conditions of 2-8°C.-Fineline Info & Tech
Leave a Reply